Nancy Cross

Bimekizumab versus Adalimumab in Plaque Psoriasis

Richard B. Warren, Andrew Blauvelt, Jerry Bagel et al. · New England Journal of Medicine · 2021 · 238 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Kim Papp, Joseph F. Merola, Alice B. Gottlieb et al. · Journal of the American Academy of Dermatology · 2018 · 188 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

The Congenital Heart Disease Genetic Network Study

Bruce D. Gelb, Martina Brueckner, Wendy Chung et al. · Circulation Research · 2013 · 167 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs

Nancy Cross, Cécile van Steen, Yasmina Zegaoui et al. · Clinical ophthalmology · 2022 · 139 citations · Full text

Medicine, Ophthalmology, Vision Science +17

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Andrew Blauvelt, Kim Papp, Joseph F. Merola et al. · Journal of the American Academy of Dermatology · 2020 · 61 citations

Life Sciences, Pharmacology, Pharmacotherapy +13